Ifinatamab deruxtecan

Indicated For

Extensive-stage small cell lung cancer

About This Medication

# Merck Patient Assistance Program Patient Guide: How to Get Ifinatamab deruxtecan at Low or No Cost Ifinatamab deruxtecan is an investigational antibody-drug conjugate being co-developed by Daiichi Sankyo and Merck for certain cancers, and the **Merck Patient Assistance Program (Merck PAP)** may provide it at no cost to eligible uninsured US residents with financial need.[1][2][8] ## About Ifinatamab Deruxtecan **Ifinatamab deruxtecan** (also known as I-DXd) targets B7-H3, a protein often overexpressed in solid tumors like small cell lung cancer and other advanced cancers. It combines a monoclonal antibody with a potent chemotherapy payload to deliver treatment directly to cancer cells, potentially minimizing damage to healthy tissue. Developed jointly by **Daiichi Sankyo and Merck**, it is administered intravenously in a clinical or hospital setting under medical supervision. As of 2026, it may be available through manufacturer patient assistance programs for eligible patients facing high costs.[1][2] This guide explains how the Merck PAP can help you access this medication if you qualify. The program offers free Merck medicines to those without prescription coverage and meeting income criteria, though specific thresholds for Ifinatamab deruxtecan follow general Merck guidelines (typically 400-500% of the Federal Poverty Level, verified electronically or via documents).[1][3][8] ## Who Qualifies for Merck PAP? To enroll, you must meet **three key criteria**:[1][5][8] - **Residency**: Live in the US or US territory (no citizenship required).[1][2] - **Prescription**: Have a prescription for a covered Merck product like Ifinatamab deruxtecan from a US-licensed healthcare provider.[1][5] - **No Insurance Coverage**: Lack health insurance or other third-party coverage for the medication. This excludes patients with employer plans that require PAP application.[1][5] **Financial Need**: Income is verified electronically via credit report (no impact on your score) or supporting documents. Specific thresholds aren't listed per drug but are checked against federal guidelines. Enrollment lasts up to **12 months**, with possible annual limits.[6][8] ## Income Eligibility Breakdown Merck PAP uses household income limits, often around **400-500% of the Federal Poverty Level (FPL)**, adjusted for household size. Exact figures aren't drug-specific in sources, but here's a general table based on program standards (2026 FPL estimates; confirm current at merckhelps.com).[3][8] | Household Size | Max Annual Income (approx. 500% FPL) | |---------------|-------------------------------------| | 1 | $73,000 | | 2 | $98,000 | | 3 | $124,000 | | 4 | $149,000 | | 5 | $175,000 | | +1 person | +$26,000 | *Note: These are estimates; program verifies electronically. Provide docs like tax returns if needed.*[1][3][8] ## Insurance Requirements You **must not have prescription coverage** for Ifinatamab deruxtecan. This includes: - Private insurance, Medicare Part D, Medicaid (in some cases), or VA coverage.[1][5] - Employer plans directing you to PAP.[1] Medicare patients are often ineligible unless in the coverage gap with no assistance. Call **800-727-5400** to confirm.[3][8] If insured, explore Merck Access Program co-pay help first.[5][9] ## Step-by-Step Application Process 1. **Check Eligibility**: Visit merckhelps.com or call **800-727-5400** (Mon-Fri, 8 AM-8 PM ET).[2][8] 2. **Download Form**: Get the enrollment form from merckhelps.com/MPAP or call for one.[1][2] 3. **Patient Section**: Fill Section 1 (personal info), sign/date Sections 2-3, authorize electronic income check or attach proof (e.g., 1040, W-2, pay stubs).[1][8] 4. **Provider Section**: Take to your doctor; they complete Sections 4-5, include NPI, prescription details, sign/date.[1][8] 5. **Submit**: Mail original form to Merck PAP (address on form). No copies; fax for vaccines only.[1][3][6] 6. **Urgent Needs**: Call 800-727-5400 for expedited help.[8] **Required Documents** (if no electronic verification): - One of: Federal tax return, W-2, pay stubs (last 4 weeks), SSI/SSD award letter, unemployment statement.[1][4][8] ## Timeline and Delivery - **Processing**: 2 weeks typically if complete; under 7 business days if eligible. Delays if incomplete.[3][7][8] - **Approval Notification**: Provider and patient contacted; medicine shipped to doctor's office or pharmacy.[1][8] - **Delivery**: Free to prescriber's office; pick up there. Up to 12-month supply, limited by calendar year.[6][8] ## Alternatives if Denied - **Appeal**: Provide missing info or updated documents.[3] - **Other Programs**: Daiichi Sankyo PAP (if separate), RxHope, NeedyMeds, or state assistance.[6] - **Co-Pay Cards**: Merck Access Program for insured (855-257-3932).[5][9] - **Patient Access Network (PAN) Foundation** or CancerCare for grants. - **Clinical Trials**: Search clinicaltrials.gov for Ifinatamab deruxtecan studies. ## Refills and Reauthorization Annual reapplication required after 12 months. Provider must renew prescription; resubmit form.[6][8] ## Disclaimer This guide is for informational purposes based on available Merck PAP details as of 2026. Eligibility, coverage for Ifinatamab deruxtecan, and terms can change. Always verify at merckhelps.com or 800-727-5400. Not medical/financial advice; consult your doctor and advisor. Program reserves audit rights.[1][3][8] (Word count: 950)

Program information last verified: March 30, 2026